2018
DOI: 10.1111/bjd.16936
|View full text |Cite
|
Sign up to set email alerts
|

Identification of a unique Staphylococcus aureus ribosomal signature in severe atopic dermatitis

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

2
4
0

Year Published

2019
2019
2022
2022

Publication Types

Select...
5

Relationship

1
4

Authors

Journals

citations
Cited by 6 publications
(6 citation statements)
references
References 8 publications
2
4
0
Order By: Relevance
“…B,E), consistent with previous reports . We previously leveraged the high‐resolution microbial community profiling enabled by the SMURF method and identified specific sAD‐associated S. aureus 16S sequences .…”
Section: Discussionsupporting
confidence: 87%
See 1 more Smart Citation
“…B,E), consistent with previous reports . We previously leveraged the high‐resolution microbial community profiling enabled by the SMURF method and identified specific sAD‐associated S. aureus 16S sequences .…”
Section: Discussionsupporting
confidence: 87%
“…1B,E), consistent with previous reports (13,18,38). We previously leveraged the high-resolution microbial community profiling enabled by the SMURF method (30) and identified specific sAD-associated S. aureus 16S sequences (39). Dead Sea climatotherapy is a proven modality for the treatment of a variety of skin diseases, including AD (19).…”
Section: Discussionsupporting
confidence: 83%
“…Interestingly, only an increase in Staphylococcus relative abundance, and specifically Staphylococcus aureus, was observed in these studies, which also correlated positively with SCORAD [41,44,45]. S. aureus is an important pathogen in atopic dermatitis, as it is a dominant member of the cutaneous bacterial composition in most AD patients [44,46]. Although increased S. aureus abundance is strongly linked to AD severity, the role of Staphylococci in the establishment of AD had not been investigated until recently.…”
Section: The Skin Microbiome In Atopic Dermatitismentioning
confidence: 84%
“…Regarding WHO region, the majority of studies were conducted in the European Region ( n = 50, 55%), followed by the Western Pacific Region ( n = 21, 23%), the Region of the Americas ( n = 16, 18%) and the African Region and the Eastern Mediterranean Region (both n = 1, 1%). Investigated characteristics included the following categories: skin barrier function ( n = 15), 19–33 serum blood cell types and markers ( n = 23), 9,18,23,34–53 serum Ig levels and sensitization ( n = 15), 20,22,25,51,54–64 microbial colonization ( n = 10), 15,65–73 DNA mutations ( n = 14), 10,51,74–85 skin parameters ( n = 8), 32,86–92 personal and family history of allergy ( n = 4), 58,93–95 comorbidities ( n = 7), 8,51,96–100 morphology ( n = 3) 51,93,101 and other characteristics ( n = 5) 51,95,102–104 (see Table a and Appendix , Supporting Information).…”
Section: Resultsmentioning
confidence: 99%
“…Regarding WHO region, the majority of studies were conducted in the European Region (n = 50, 55%), followed by the Western Pacific Region (n = 21, 23%), the Region of the Americas (n = 16, 18%) and the African Region and the Eastern Mediterranean Region (both n = 1, 1%). Investigated characteristics included the following categories: skin barrier function (n = 15), [19][20][21][22][23][24][25][26][27][28][29][30][31][32][33] serum blood cell types and markers (n = 23), 9,18,23,[34][35][36][37][38][39][40][41][42][43][44][45][46][47][48][49][50][51][52][53] serum Ig levels and sensitization (n = 15), 20,22,25,51,54-64 microbial colonization (n = 10), 15,[65][66][67][68][69][70][71][72][73] DNA mutations (n = 14), 10,51,…”
Section: Phenotypes Based On Disease Severity (Phenotype Group 1)mentioning
confidence: 99%